Your Subscription

We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.





Login
Twitter LinkedIn




Login
  • Home
  • About
  • Updates
  • Awards
  • Contact
  • Directory
  • OnDemand
  • Partners
  • Testimonials
Forward Share Print
Smart & Biggar

CADTH harmonises drug reimbursement review process

Newsletters

11 November 2020

Healthcare & Life Sciences Canada


On 30 September 2020 the Canadian Agency for Drugs and Technologies in Health (CADTH) announced the launch of new Procedures for CADTH Drug Reimbursement Reviews (updated on 29 October 2020), which harmonise procedures under the CADTH's drug reimbursement review pathways (Common Drug Review, pan-Canadian Oncology Drug Review and Interim Plasma Protein Product Review). Notable highlights include:

  • the opportunity for drug manufacturers to comment on draft review reports;
  • posting of draft recommendations for stakeholder feedback; and
  • introduction of categories in the reconsideration process to promote flexibility.

For further information on this topic please contact Brandon Heard at Smart & Biggar by telephone (+1 416 593 5514) or email (brheard@smart-biggar.ca). The Smart & Biggar website can be accessed at www.smart-biggar.ca.

The materials contained on this website are for general information purposes only and are subject to the disclaimer.

ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.

Forward Share Print

Author

Brandon Heard

Brandon Heard

Register now for your free newsletter

View recent newsletter

More from this firm

  • Innovators challenge final PMPRB Guidelines in new Federal Court application
  • Few significant changes made in final PMPRB guidelines
  • Federal Court orders minister of health to issue NOC to Fresenius Kabi for biosimilar
  • Health Canada issues interim order respecting drug shortages relating to COVID-19
  • New interim order for COVID-19 drugs has wide-reaching impact

More articles

  • Home
  • About
  • Updates
  • Awards
  • Contact
  • My account
  • Directory
  • OnDemand
  • Partners
  • Testimonials
  • Follow on Twitter
  • Follow on LinkedIn
  • Disclaimer
  • Privacy policy
  • GDPR Compliance
  • Terms
  • Cookie policy
Online Media Partners
Inter-Pacific Bar Association (IPBA) International Bar Association (IBA) European Company Lawyers Association (ECLA) Association of Corporate Counsel (ACC) American Bar Association Section of International Law (ABA)

© 1997-2021 Law Business Research

You need to be logged in to make a comment. Log in here.
Many thanks. Your comment has been sent.

Your details



Your comment or question *